The advantages of performing corneal cross-linking (CXL) at the slit lamp are well established. It brings CXL out of the operating theater, to anywhere where
This week saw the publication of ELZA’s better pain management protocol in the Journal of Clinical Medicine, and represents a significant advance in the way pain
Newsflash: CXL reimbursed in Switzerland
Exactly 20 years after the clinical introduction of cross-linking and after more than 2,000 scientific publications on the subject, corneal cross-linking (CXL) for the treatment of progressive keratoconus has now been included in the Swiss healthcare reimbursement system (the “krankenkasse”).
In science, there is a mantra: “publish or perish”. However, there are almost 30,000 academic journals, and quantity does not equal quality. One of the
People with Down Syndrome have a disproportionately higher risk of developing keratoconus than the general population, and many go on to receive corneal cross-linking (CXL)
Can combining corneal OCT and air puff tonometry help better diagnose the earliest stages of keratoconus? That was the question ELZA researcher, Dr. Nanji Lu,
The Brazilian Association of Cataract and Refractive Surgery (BRASCRS) awarded the ELZA Institute’s Dr. Emilio Torres-Netto the José Ignacio Barraquer Medal, in recognition of his
Dr. Emilio Torres-Netto, MD, PhD, is a cornea and cataract surgeon at the ELZA Institute in Zurich. Emilio was featured in this month’s issue of
Our latest review on “CXL in thin corneas”. It describes all current approaches how to treat thin keratoconus corneas using corneal cross-linking, including our original approach of swelling the cornea and our latest approach, the sub400 protocol.
Photoactivated chromophore for keratitis-corneal cross-linking (PACK-CXL) has progressed a great deal since it was first developed (1) as a treatment for infectious keratitis and corneal
